Immunome (NASDAQ:IMNM) Downgraded by Wall Street Zen to “Sell”

Immunome (NASDAQ:IMNM) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

IMNM has been the topic of several other research reports. HC Wainwright assumed coverage on Immunome in a report on Thursday, February 12th. They set a “buy” rating and a $40.00 price objective on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunome in a report on Thursday, January 22nd. Craig Hallum lifted their target price on shares of Immunome from $33.00 to $36.00 and gave the stock a “buy” rating in a research report on Wednesday. Guggenheim boosted their price target on shares of Immunome from $25.00 to $35.00 and gave the company a “buy” rating in a report on Tuesday, December 16th. Finally, Wedbush restated an “outperform” rating and issued a $31.00 price target on shares of Immunome in a research report on Thursday, January 15th. Eleven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $32.33.

Immunome Trading Up 0.4%

Shares of NASDAQ IMNM opened at $21.04 on Friday. Immunome has a twelve month low of $5.15 and a twelve month high of $27.65. The firm has a 50-day moving average of $22.74 and a two-hundred day moving average of $17.67. The company has a market capitalization of $2.38 billion, a price-to-earnings ratio of -8.69 and a beta of 2.12.

Immunome (NASDAQ:IMNM) last released its earnings results on Tuesday, March 3rd. The company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.10). Immunome had a negative return on equity of 57.61% and a negative net margin of 1,687.08%. As a group, research analysts predict that Immunome will post -2.21 earnings per share for the current year.

Insider Transactions at Immunome

In related news, insider Philip Tsai bought 10,000 shares of the firm’s stock in a transaction on Friday, December 19th. The stock was purchased at an average price of $20.49 per share, with a total value of $204,900.00. Following the completion of the transaction, the insider directly owned 43,300 shares of the company’s stock, valued at $887,217. This trade represents a 30.03% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Clay B. Siegall purchased 4,729 shares of the company’s stock in a transaction dated Tuesday, December 30th. The stock was purchased at an average cost of $21.15 per share, for a total transaction of $100,018.35. Following the transaction, the chief executive officer owned 665,254 shares of the company’s stock, valued at approximately $14,070,122.10. This trade represents a 0.72% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders purchased 68,518 shares of company stock worth $1,453,958. 7.69% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Immunome

A number of institutional investors have recently made changes to their positions in the business. T. Rowe Price Investment Management Inc. raised its holdings in Immunome by 59.4% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 13,421,987 shares of the company’s stock valued at $288,305,000 after acquiring an additional 5,003,824 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Immunome by 23.4% during the 4th quarter. Vanguard Group Inc. now owns 6,038,414 shares of the company’s stock worth $129,705,000 after purchasing an additional 1,144,788 shares in the last quarter. Primecap Management Co. CA grew its holdings in shares of Immunome by 55.2% during the 4th quarter. Primecap Management Co. CA now owns 4,685,441 shares of the company’s stock worth $100,643,000 after purchasing an additional 1,667,432 shares in the last quarter. State Street Corp increased its position in shares of Immunome by 37.9% during the fourth quarter. State Street Corp now owns 3,868,000 shares of the company’s stock valued at $83,085,000 after purchasing an additional 1,064,027 shares during the period. Finally, JPMorgan Chase & Co. increased its position in shares of Immunome by 8,659.2% during the fourth quarter. JPMorgan Chase & Co. now owns 2,855,747 shares of the company’s stock valued at $61,341,000 after purchasing an additional 2,823,144 shares during the period. 44.58% of the stock is currently owned by institutional investors.

Immunome News Summary

Here are the key news stories impacting Immunome this week:

• Positive Sentiment: HC Wainwright raised multiple 2026 quarterly EPS forecasts (Q1: from ($0.68) to ($0.53); Q2: ($0.70) to ($0.55); Q3: ($0.72) to ($0.56); Q4: ($0.68) to ($0.58)) and lifted FY2026 estimate to ($2.21) from ($2.78). These narrower loss projections suggest better near‑term operating performance. Article Link
• Positive Sentiment: HC Wainwright also boosted FY2027 (from ($2.20) to ($1.81)) and FY2028 (from ($0.79) to ($0.54)) estimates, implying a faster path toward profitability than previously modeled — a material positive for valuation assumptions. Article Link
• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and a $40 price target while raising FY2029 and FY2030 profit forecasts (FY2029: $0.69 from $0.63; FY2030: $1.35 from $1.28), reinforcing a bullish long‑term view that likely helped buying interest. Article Link
• Neutral Sentiment: Despite the upgrades, HC Wainwright still models losses through FY2028 (FY2026 consensus remains around ($2.21)), so the company is viewed as a longer‑duration growth/turnaround investment rather than near‑term profitable. Article Link

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.